Leish G1 Cream
Treatment of Cutaneous Leishmaniasis
Garlic extract standardized by allicin 0.07%

Experience the extraordinary potential of garlic extract with Behpad’s groundbreaking product, Leish G1 Cream, in the fight against cutaneous leishmaniasis—a widespread and devastating disease affecting populations around the world. As a pandemic illness, cutaneous leishmaniasis poses significant challenges, with limited successful endeavors to combat its impact on global health.

Cutaneous leishmaniasis is a neglected tropical disease caused by the Leishmania parasite, transmitted through the bites of infected sandflies. It manifests as skin lesions, ulcers, and nodules, often leading to disfigurement, disability, and severe social stigmatization. The World Health Organization estimates that over one million new cases occur annually, making it one of the most prevalent vector-borne diseases worldwide.

 

Despite the global burden of cutaneous leishmaniasis, effective treatments and interventions remain scarce. This scarcity necessitates innovative solutions that can address the urgent need for safe, accessible, and efficacious therapies. Behpad recognizes this pressing challenge and has developed Leish G1 Cream as a significant step forward in combating this devastating disease.

Integrating the remarkable effects of garlic extract, Leish G1 Cream offers a breakthrough immunomodulatory approach. Numerous studies have demonstrated the growth inhibition of Leishmania promastigotes and reduction of amastigotes within infected macrophages, showcasing the potential of garlic extract in targeting the parasite. By activating macrophages, inducing apoptosis, and exerting direct cytotoxic effects, this innovative cream unleashes the immune system’s power to combat the Leishmania parasite effectively.

Moreover, the immunomodulator derived from garlic extract in Leish G1 Cream addresses the complex mechanisms that contribute to the parasite’s survival. By enhancing the secretion of Th1 cytokines and boosting macrophage responses, it reinvigorates the immune system, thus fostering a more robust defense against Leishmania. This comprehensive approach represents a significant advancement in the treatment of cutaneous leishmaniasis, offering hope and relief to millions of affected individuals worldwide.

Leish G1 Cream provides a range of advantages that further solidify its position as a groundbreaking solution for cutaneous leishmaniasis:

  • Leish G1 Cream prevents eschar formation when used in the early stages of wounding or minor wounds. By addressing the wound at an early stage, it promotes optimal healing outcomes, preventing the development of eschars and facilitating a more efficient recovery process.
  • The cream not only treats cutaneous leishmaniasis but also aids in repairing lesions through several mechanisms. Its immunomodulatory properties enhance the immune response against the parasite, leading to the resolution of lesions and promoting healthy tissue regeneration.
  • Beyond its primary indication, Leish G1 Cream is also effective in treating various cutaneous infected lesions. Its multifaceted action targets the underlying infection, facilitating the healing process and improving overall patient outcomes.

By incorporating these advantages, Leish G1 Cream provides a comprehensive solution that addresses the unique challenges posed by cutaneous leishmaniasis. Its ability to prevent eschar formation, improve wound healing, and treat a range of infected lesions exemplifies the cream’s efficacy and versatility.

It is worth noting that very few endeavors exist that have successfully combated the challenges posed by cutaneous leishmaniasis. As such, Behpad’s commitment to research and development, as well as the proven efficacy of Leish G1 Cream, distinguishes it as a pioneering force in the fight against this devastating disease. The cream’s advanced formulation, supported by extensive scientific literature, positions it as a breakthrough solution that addresses the urgent global health concern presented by cutaneous leishmaniasis.

Behpad remains committed to advancing the field of cutaneous leishmaniasis treatment through continuous research and development efforts. By providing Leish G1 Cream, we strive to make a meaningful impact on the lives of individuals affected by this devastating disease. Together, let us forge ahead in the battle against cutaneous leishmaniasis, bringing hope, healing, and a brighter future to communities worldwide.

Indication:

✔ Treatment of Cutaneous Leishmaniasis
✔ Treatment of cutaneous infected lesion

 

Direction: Adults use twice a day topically on leishmaniasis skin lesions

Packaging: 30g tube

LeishG1-price

References:

✔ Ghazanfari, T., Hassan, Z. M., & Ebrahimi, M. (2002). Immunomodulatory activity of a protein isolated from garlic extract on delayed type hypersensitivity. International immunopharmacology, 2(11), 1541-1549.

✔ Ghazanfari, T., Yaraee, Roya, Asoode, A., Rajabian, T., Kardar, M., Hassan, Z. M., … & Jamali, D. (2009). Purification of Immunomodulator Fraction Components of Garlic (R10) by HPLC. Journal of Medicinal Plants, 8(29), 100-106.

✔ Radjabian, T., Hosseinpur Yektaei, Z., Ghazanfari, T., Nasiri, Z., & Fotovvat, M. (2019). The immunoregulatory effects of four Allium species on macrophages and lymphocytes viability. Immunoregulation, 2(1), 25-34.

✔ Ghazanfari, T., Hassan, Z. M., & Khamesipour, A. (2006). Enhancement of peritoneal macrophage phagocytic activity against Leishmania major by garlic (Allium sativum) treatment. Journal of Ethnopharmacology, 103(3), 333-337.

✔ Ghazanfari, T., Hassan, Z. M., Ebtekar, M., Ahmadiani, A., Naderi, G., & Azar, A. (2000). Garlic induces a shift in cytokine pattern in Leishmania major‐infected Balb/c mice. Scandinavian Journal of Immunology, 52(5), 491-495.</span>